BlueSphere Bio

About

BlueSphere Bio is a clinical-stage biotechnology company based in Pittsburgh, PA, founded in 2017. The company focuses on developing personalized T cell receptor (TCR)-based immunotherapies for cancer treatment. BlueSphere was the first translational sciences biotech startup formed by UPMC Enterprises. Its mission is to rapidly screen, identify, and validate TCR-based therapies for accelerated delivery to the clinic, emphasizing the uniqueness of each cancer and the need for personalized treatments. The company's core innovation is the TCXpress platform, an automated TCR discovery system that utilizes patients' immune defenses to target their specific cancers. BlueSphere's lead program, TCX-101, is being tested for hematologic malignancies, while TCX-201 is in development for solid tumors. The company is also exploring treatments for rare diseases through a collaboration with the National Cancer Institute. In June 2024, BlueSphere received FDA IND clearance for its first-in-human TCR therapy targeting high-risk leukemia. The leadership team includes CEO Keir Loiacono and prominent scientists in the field.